Woodstock Corp lowered its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 12.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 107,357 shares of the biopharmaceutical company's stock after selling 15,767 shares during the quarter. Woodstock Corp's holdings in Pfizer were worth $2,848,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Charles Schwab Investment Management Inc. increased its position in Pfizer by 11.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock worth $3,766,366,000 after purchasing an additional 12,864,343 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Pfizer by 279.3% in the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company's stock worth $150,481,000 after buying an additional 8,378,173 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Pfizer by 22.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock valued at $1,101,713,000 after buying an additional 6,977,587 shares in the last quarter. International Assets Investment Management LLC purchased a new position in Pfizer in the third quarter worth about $146,481,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Pfizer by 164.2% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,316,405 shares of the biopharmaceutical company's stock worth $211,737,000 after acquiring an additional 4,546,809 shares during the last quarter. Institutional investors own 68.36% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on PFE shares. Sanford C. Bernstein assumed coverage on Pfizer in a report on Thursday, October 17th. They issued a "market perform" rating and a $32.00 target price for the company. Bank of America reiterated a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Cantor Fitzgerald restated an "overweight" rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 8th. Finally, Wolfe Research initiated coverage on Pfizer in a research report on Friday, November 15th. They set an "underperform" rating and a $25.00 target price for the company. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $32.00.
Check Out Our Latest Stock Report on Pfizer
Insider Buying and Selling
In related news, Director Scott Gottlieb acquired 1,000 shares of the business's stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at $282,400. The trade was a 11.11 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by company insiders.
Pfizer Stock Down 0.7 %
PFE stock traded down $0.19 during trading on Friday, hitting $26.30. 35,085,970 shares of the company's stock traded hands, compared to its average volume of 32,677,234. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $149.06 billion, a P/E ratio of 35.55, a PEG ratio of 0.64 and a beta of 0.64. The business has a fifty day simple moving average of $26.09 and a two-hundred day simple moving average of $28.00. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business's revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.17) EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current year.
Pfizer Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.54%. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer's previous quarterly dividend of $0.42. Pfizer's dividend payout ratio is currently 227.03%.
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
